Gabrielle M. Siegers

Gabrielle M. Siegers has a strong background in research and development, particularly in the field of immunotherapy. In 2001, they began their career as a PhD student at the Max Planck Institute for Immunology and Epigenetics, where they conducted research until 2007. Following this, they worked as a postdoctoral fellow in the Cell Therapy Department at Princess Margaret Hospital & Robarts Research Institute, where they focused on investigating cytotoxic human gamma delta T cells for cancer immunotherapy and cellular MRI. From 2012 to 2014, they continued their postdoctoral work in the Department of Anatomy and Cell Biology.

In 2014, Gabrielle joined the University of Alberta as a Research Scientist, where they designed and carried out research projects on gamma delta T cell immunotherapy for breast and ovarian cancer. Gabrielle M.'srole also involved supervising PhD students and writing research articles and reviews. Gabrielle M. remained with the University of Alberta until 2020.

In 2021, Gabrielle worked as an Independent Consultant before joining IN8bio as a Senior Scientist and Gamma Delta T Cell Specialist from July 2021 to July 2022. Presently, they hold the position of Head of Research and Development at Helix Biopharma Corp.

Gabrielle M. Siegers has a PhD in Molecular Immunology from The University of Freiburg, which they obtained between the years 2001 and 2007. Prior to that, they pursued their MA in German Studies at Queen's University from 1997 to 1999. Gabrielle M. completed their undergraduate education at the University of Guelph from 1992 to 1996, where they earned their HBSc in Biochemistry and German. The information provided does not include any details about their education at Western University.